Welcome to our dedicated page for Bluebird Bio news (Ticker: BLUE), a resource for investors and traders seeking the latest updates and insights on Bluebird Bio stock.
This page aggregates historical BLUE (bluebird bio, Inc.) news, capturing the company’s evolution as a commercial-stage gene therapy business and its transition from a public to a private company. Founded in 2010 and headquartered in Somerville, Massachusetts, bluebird bio describes itself as having set the standard for gene therapy for more than a decade, with FDA-approved therapies for sickle cell disease, β-thalassemia, and cerebral adrenoleukodystrophy.
News items for BLUE include corporate and transaction announcements, such as the February 21, 2025 definitive agreement to be acquired and taken private by funds managed by Carlyle and SK Capital, subsequent updates on the tender offer, regulatory approvals, and the June 2, 2025 announcement that the sale had closed and that bluebird’s common stock had ceased trading and would no longer be publicly listed.
In addition to deal-related coverage, bluebird’s releases provide context on its gene therapy platform, including references to its ex-vivo gene therapy data set, three FDA-approved therapies, and focus on access for patients, providers, and payers. Communications also highlight the company’s emphasis on safety analytics for lentiviral vector technologies and its work to expand manufacturing capacity and support treatment centers.
Investors, researchers, and industry observers can use this BLUE news feed to review the timeline of strategic decisions, financing events, and ownership changes that shaped bluebird bio’s path, as well as the company’s own description of its role in gene therapy for severe genetic diseases. Bookmark this page to quickly reference past press releases and transaction milestones associated with the former NASDAQ-listed ticker BLUE.
bluebird bio, Inc. (Nasdaq: BLUE) will discuss its first quarter 2024 results and business updates on May 9 at 8:00 a.m. ET. The company will also participate in investor conferences on May 16 and June 12. Investors can access the live webcasts on bluebird bio's website.
bluebird bio, Inc. announced the completion of the first commercial cell collection for LYFGENIA gene therapy, a one-time treatment for sickle cell disease. LYFGENIA was FDA-approved in December 2023 and is the most extensively studied gene therapy for the disease. The cells were collected at Children’s National Hospital in Washington, DC, marking a significant milestone in the treatment of sickle cell disease.
FAQ
What is the current stock price of Bluebird Bio (BLUE)?
What is the market cap of Bluebird Bio (BLUE)?
